What Is Hot and New in Basic and Translational Science in Liver Transplantation in 2022? Report of the Basic and Translational Research Committee of the International Liver Transplantation Society
Journal
Transplantation
Journal Volume
107
Journal Issue
4
Date Issued
2023-04-01
Author(s)
Bhat, Mamatha
Dondossola, Daniele
Varghese, Rhea
Czigany, Zoltan
Emamaullee, Juliet
Ghinolfi, Davide
Al-Adra, David
Bonaccorsi-Riani, Eliano
Pang, Li
Boteon, Yuri L
Brüggenwirth, Isabel
Pavan-Guimaraes, Juliana
Yuksel, Muhammed
Zarrinpar, Ali
Abdelrahim, Maen
Barbas, Andrew S
Mas, Valeria
Selzner, Markus
Martins, Paulo N
Abstract
INTRODUCTION The 2022 Joint Annual Congress of the International Liver Transplantation Society (ILTS), European Liver and Intestine Transplant Association, and Liver Intensive Care Group of Europe was held in Istanbul, Turkey, from May 4 to 7, 2022. The meeting was held in a hybrid format with excellent in-person and online engagement. This was the first time in 2 y that the ILTS community was able to meet in-person, enabling rich networking opportunities and extensive discussion. The ILTS Congress was attended by 1123 delegates from 61 countries (648 participants on-site and 475 online; Figure 1).FIGURE 1.: Countries with (A) ≥10 delegates and (B) the presenting authors of basic and translational science abstracts at the 2022 Joint ILTS-ELITA-LICAGE Meeting. This figure was regenerated with permission of the ILTS. The authors and the journal remain neutral with regard to jurisdictional claims in published maps and institutional affiliations. ELITA, European Liver and Intestine Transplantation Association; ILTS, International Liver Transplant Society; LICAGE, Liver Intensive Care Group of Europe; SAR, Special Administrative Region.Out of a total of 465 abstracts, 9.9% fell into the basic/translational science category, representing a 1.7% increase in basic/translational abstracts compared with the previous year (Table 1). This is reflective of the increasing enthusiasm for basic science research to elucidate a mechanistic understanding of transplant processes among the ILTS membership. Beyond the original research presented orally at 2 Basic and Translational Science abstract sessions, the Basic and Translational Science Research Committee was also responsible for the organization of a well-received workshop on multiomics and big data in liver transplantation organized by the Basic and Translational Science Research Committee. In addition, a joint workshop was held with the precision medicine and biomarkers special interest groups from ILTS. Our committee also organized an especially well-received and fully booked pre-Congress “hands on” workshop on machine perfusion preservation in conjunction with local transplant leaders in Istanbul and members of the Toronto transplant research team. TABLE 1. - Absolute and relative frequencies of basic and translational science–related abstracts presented at the Joint ILTS-ELITA-LICAGE Meetings in 2017–2021 Year/venue Countries represented (n) Total abstracts (n) Late-breaking abstracts (n) Basic and translational research abstracts (n) Basic and translational research abstracts (%) 2017/Prague 61 860 65 70 8.1 2018/Lisbon 58 759 112 72 9.5 2019/Toronto 52 900 74 75 8.3 2020–2021/virtual a 66 730 89 60 8.2 2022/Istanbul 61 465 76 46 9.9 aBecause of the coronavirus disease 2019 pandemic, the 2020 ILTS Congress in Istanbul was postponed and held in a fully virtual setting in 2021.ELITA, European Liver and Intestine Transplant Association; ILTS, International Liver Transplantation Society; LICAGE, Liver Intensive Care Group of Europe. Here, we summarize key basic and translational science abstracts categorized into 4 main themes, including (1) ischemia–reperfusion injury (IRI) and machine perfusion, (2) transplant oncology, (3) novel biomarkers, and (4) liver immunobiology (Figure 2). These abstracts used animal models and profiling of patient samples using multiomics approaches and laboratory techniques, including single-cell sequencing and imaging mass cytometry. We will attempt to place these results in the context of the current literature, thereby demonstrating how these studies promise to advance the field.FIGURE 2.: Sankey diagram depicting distribution of abstract topics and main techniques used in the 46 basic science studies presented at the 2022 Joint ILTS-ELITA-LICAGE Meeting.* *Each (total N = 46) abstract has been classified into 1 of the 4 topics/themes and based on the main technique and methodical approach used. ELITA, European Liver and Intestine Transplantation Association; ILTS, International Liver Transplant Society; IRI, ischemia–reperfusion injury; LICAGE, Liver Intensive Care Group of Europe.IRI and Machine Perfusion IRI is a ubiquitous and unavoidable consequence in all solid organ transplantation with a special impact on liver transplantation (LT). In fact, IRI represents the sum of damages that accumulates at each stage of the transplantation process, from the onset of the hypoxia/ischemia phase in the donor (eg, aortic cross-clamp) to reperfusion in the recipient. The degree of IRI directly affects posttransplant organ function and the rate/severity of post-LT complications.1 Notably, the more extended criteria characteristics the graft has (eg, steatosis, advanced age, ischemia time), the more susceptible it will be to IRI. In this year’s ILTS Congress, different studies focused their attention on IRI evaluation and its modulation through both machine perfusion and pharmacological treatments. Evaluation of IRI Cell culture, liver resection, in vivo IRI (liver hilum clamping), and transplantation models are all used for the evaluation of the IRI and to provide deeper insight into IRI machinery. An activated inflammatory cascade and a reduced energetic pool secondary to IRI are commonly identified as key events that lead to lower results after LT using steatotic grafts. McDaniels et al (J. McDaniels, MDD, unpublished data) investigated the particular susceptibility of steatotic liver grafts to IRI. They used single-cell transcriptomic analyses on steatotic and normal human hepatocytes and were able to confirm a decrease in coagulation factors, increase in proinflammatory profiles, and activation of peroxidation during IRI in fatty liver hepatocytes, confirming in vivo experimental data. In addition, single-cell transcriptomic analysis was able to identify pathways that may represent targets for IRI therapeutic intervention and factors that could reduce regenerative capacity post-IRI.2 Bardhi et al3 explored the role of micro-RNAs (miRNAs) in the regulation of donor organ damage on human liver biopsies. They further emphasized the upregulation and downregulation of these miRNAs and found specific miRNAs that could serve as potential therapeutic targets,3 a promising approach to reduce early graft dysfunction.4 Normothermic Machine Perfusion Machine perfusion preservation represents one of the most promising and translational technology in the field of IRI prevention and treatment from a clinical and research perspective. Although hypothermic oxygenated machine perfusion (HOPE) achieved significant results in the clinical setting, normothermic machine perfusion (NMP) reserves the opportunity to maintain liver graft physiology and assess liver homeostatic functions.5 At this year’s Congress, a higher number of abstracts were focused on the application of NMP technology (Table 2). Several groups explored the possibility of NMP to prolong ex situ preservation. Building on these results, Lau et al used a modified commercial NMP system (with dialysis filter) to surgically split human livers without interrupting perfusion and preserve them for several days. As a result, the grafts were able to meet the viability criteria for as long as 13 d.6 The same group showed that, after 72 h NMP, biliary reepithelialization could occur, and biliary viability criteria could be met even by grafts that did not meet them at the beginning of NMP.7 As long as NMP can be prolonged, more opportunities for ex situ organ treatment could be achieved. Despite these promising prospects, a more thorough evaluation of the mechanisms of NMP is needed to better understand these findings and fully exploit the potential for NMP preservation, treatment, and reconditioning. In a metabolomics study of an NMP rat model, Lonati et al8 demonstrated that even in the presence of physiological oxygen supply, numerous changes in energy, glucose, mitochondrial and lipid metabolism, and redox occur during NMP. These findings are consistent with previous observations on the regulation of metabolic pathways in early allograft dysfunction (EAD) and phospholipid turnover.9 In an effort to provide a more physiological environment during ex situ perfusion, Wu et al used normothermic venoarteriovenous cross-circulation between a discarded human donor liver and an immunosuppressed, complement-deprived pig to maintain normothermic perfusion. They successfully preserved biliary integrity and gross architecture for 24 h, but clinical application is still far off.10 TABLE 2. - Summary of the main findings on machine perfusion explored in the 2022 ILTS Congress Author Model Preservation modality Aim Key findings Lau et al 6 Human-discarded liver NMP Prolong perfusion After ex situ liver split, liver graft viability criteria were maintained up to 13 d Lau et al 6 Human-discarded liver NMP Bile duct evaluation After 72 h, bile reepithelialization was observed Lonati et al Rat NMP Metabolic profiling during NMP Compared with normal liver metabolism, changes in energy, glucose, mitochondrial and lipid metabolism, and redox occurred during NMP Wu et al 10 Human/pig Cross-circulation Prolong perfusion Using pig to isolated liver cross-circulation, successful preservation of human liver biliary tree, and gross architecture was observed after 24 h Panconesi et al DCD rat NRP/HOPE Mitochondrial preservation HOPE showed lower mitochondrial damage and higher survival compared with NRP Muller et al 11 DCD pig SCS/HOPE Development preservation solution Polyethylene glycol and glutathione-enriched solutions could be used for both static and dynamic hypothermic perfusion Gomez Bardallo et al 12 Obese rat SCS Development preservation solution Polyethylene glycol and glutathione-enriched solutions reduced peroxidation and mitochondrial damage in fatty liver DCD, donation after circulatory death; HOPE, hypothermic oxygenated machine perfusion; ILTS, International Liver Transplantation Society; NMP, normothermic machine perfusion; NRP, normothermic regional perfusion; SCS, static cold storage. Although prolongation of ex situ perfusion was one of the most attractive perspectives that emerged from the Congress, a deeper understanding of the exact biological mechanisms elicited during machine perfusion is essential to further progress. To achieve this goal, optimization and standardization of ex situ protocols (preclinical setting) together with more homogeneous graft quality (clinical setting) are key steps. In addition, taking advantage of the methodology of IRI and regeneration studies, the integration of results obtained by different models and advanced laboratory technologies is of paramount importance to achieving this aim. Other Dynamic Machine Perfusion Techniques Normothermic regional perfusion, an in situ perfusion approach, is widely adopted (in combination or not with other end-ischemic machine perfusion modalities) to improve donation after circulatory death outcomes. Panconesi et al directly compared normothermic regional perfusion and dual HOPE in a donation after circulatory death setting. In a rat model, the authors found lower mitochondrial damage and inflammation in the dual HOPE group as well as higher survival. The implementation of static cold storage and machine perfusion preservation solutions is needed to improve these results further. In a rat and pig model, adding polyethylene glycol and glutathione to the standard solutions during cold preservation (both static and dynamic) allows for better preservation of both lean and steatotic grafts.11,12 Alternative Approaches to Ischemia–reperfusion Modulation Besides machine perfusion, several strategies are being investigated to prevent and mitigate IRI in the LT setting. Concomitantly, multiomics approaches have been applied to elucidate the effect of different compounds on IRI.3 As a result, the search for new therapeutic approaches to mitigate IRI led to a deeper understanding of its mechanisms. Liu et al used a small-molecule macrophage migration inhibitory factor inhibitor in a rat LT model to protect liver donation after circulatory death grafts from IRI damage. Through the administration of this compound, they were able to downregulate IRI in the early reperfusion phase, thus contributing to supporting the role of migration inhibitory factor as a proinflammatory mediator in liver reperfusion.2,13 Duarte et al further investigated the role of inflammatory modulation. They used a mouse IRI model (partial hilum clamping) to evaluate the role of tryptophan immunometabolism as a possible anti-inflammatory/immunosuppressive target. By administering PEGylate-indoleamine 2,3-dioxygenase 1, they showed protection against IRI by reprogramming tryptophan immunometabolism.14 Ferroptosis was shown to be a further promising target for IRI modulation by Rokop et al.15 Indeed, in a mouse model of in situ IRI, ferroptosis was upregulated in the fatty liver group together with lipid peroxidation. Mitochondrial damage is closely related to ferroptosis, inflammation, and lipid peroxidation, whereas the degree of mitochondrial damage was related to liver survival after reperfusion in grafts subjected to machine perfusion.16 Histone deacetylase inhibition was shown by Samuvel et al17 as a protective treatment against IRI and mitochondrial damage. Histone deacetylase acts at an epigenetic level by regulating antioxidant and iNOS expression as well as suppressing NFk-B activation.18 Novel Diagnostic and Prognostic Biomarkers in LT With the complexity of LT mobilizing multiple physiological and cellular processes, there remains a sustained focus on ensuring optimal graft usage. This combined with the organ shortage fortifies the need for the inquiry into biomarkers (Table 3) that can predict and elucidate ideal graft-related outcomes. TABLE 3. - Physiological targets and discriminative abilities of novel biomarkers explored in the 2022 ILTS Congress Biomarker Physiological target Main findings Key takeaway Galectin-3 β-galactoside–binding lectin implicated in inflammation, immune regulation, and liver fibrosis 19 Predictive of early acute rejection and early allograft dysfunction in those with extended ICU stay and those undergoing dialysis Multivariable model of galectin-3 can be used to assess risk of acute rejection and allograft dysfunction Glycan composed of triantennary and fucosylated glycans and decreased amount of undergalactodylated glycans Liver sinusoid of malignant tissue 20 Discriminative pretransplant parameter of hepatocellular carcinoma recurrence Glycomics-based serum panel can improve allocation strategies for transplant candidates with HCC cfMeDIP-seq Methylation pattern on circulating DNA Noninvasive biomarker of TCMR and recurrent NASH Distinctive methylation patterns on regulatory genes can identify NASH posttransplant in a specific noninvasive way HCC, hepatocellular carcinoma; ICU, intensive care unit; ILTS, International Liver Transplantation Society; NASH, nonalcoholic steatohepatitis; TCMR, T cell–mediated rejection. Galectin-3 (Gal3) exerts various biological functions, including regulation of inflammation, angiogenesis, collagen synthesis, and cell death.21 Yoeli et al determined Gal3 to be predictive of EAD. Using citrated plasma from LT recipients 1 d after LT, they measured Gal3 in relation to outcomes surrounding EAD, intensive care unit length of stay, and posttransplant dialysis, finding a correlation between Gal3 and more prolonged intensive care unit stay. When combined with alcohol-related cirrhosis and being a non-Hispanic White, Gal3 was found to be highly predictive of EAD.22 The same group found Gal3 to be predictive of 30-d rejection post-LT. In this study, they found a significant association between transplant Gal3 and 30-d acute cellular rejection.23 Gal3 shows promise in being a predictive biomarker for outcomes posttransplant outcomes. Exploring the pathways leading to disease as well as treatment continues to be of great interest in transplant research this year. Various researchers explored paradigms of liver disease from those involving liver scarring to biliary complications. Despite recent advances in antiviral therapy, progressive liver fibrosis is a ubiquitous issue after transplantation for patients with recurrent hepatitis C.24 Fibrotic livers are unable to effectively regenerate. Nguyen-Lefebvre et al found that the regenerating fibrotic liver used different pathways different from those in normal regeneration, with regenerating fibrotic livers exhibiting reduced fibrosis when compared with control fibrotic livers. These data suggest that through the regenerative process, fibrotic liver tissue can eventually be replaced by healthy liver tissue.4,25 This cutting-edge research suggests a new avenue of research that can limit the progression of graft fibrosis. Transplant Oncology Transplant oncology is a key topic of research within the LT landscape, given that 35% to 40% of LT recipients worldwide currently undergo transplants for hepatocellular carcinoma (HCC). Abstracts in this category were mainly in the clinical category, but there were a few basic and translational abstracts also in transplant oncology. Understanding the biological mechanisms underlying response to bridging therapy or recurrence posttransplant is critical to optimizing posttransplant outcomes. HCC recurrence remains a notable issue within the LT paradigm. Vergeist et al assessed the serum protein N-glycan in patients with HCC recurrence compared with those without. Through this analysis, they developed a composite serum biomarker based on the increased presence of triantennary and fucosylated glycans and the decreased presence of undergalactosylated glycans in patients with HCC recurrence. This panel has the potential to advise allocation in transplant candidates with HCC.26 Ding et al explored fatty acid desaturase 1 (FADS1) and polyunsaturated fatty acids and their role in HCC suppression. Within mouse models, they found that in liver-specific FADS1 knockout mice, there was delayed tumor formation as well as a noted decrease in tumor mass alongside upregulation of CD8+ T cells.27 Given that a fatty liver-related oncogene drives FADS1, this work highlights the role of polyunsaturated fatty acids in posttransplant HCC recurrence. Zhe et al explored how HCC cells may protect themselves from the immune system. They examined the role of ferritin heavy chain 1 (FTH1) in tumor-derived exosomes as a protective mechanism against CD8+ T cell–associated ferroptosis, in a series of elegant in vitro and in vivo null null of null by tumor-derived exosomes led to null null CD8+ null null This was null with a ferroptosis null null they null that null expression was upregulated in HCC null and null null with null null and null null Liver null With the null of null and laboratory null the null of the biological and null null of the liver can be null In this setting, liver regeneration represents null null between biological and null mechanisms that could null place within a human null Indeed, to null a liver null several null mechanisms are elicited at local and null null The null null between cell null null and regeneration null a key role in organ null null the understanding of these events could null to not null improve the null of liver immunobiology but also improve the null of clinical null null as IRI and rejection. null null et null null from research by null et null that found null null increased the regenerative capacity of hepatocytes in mouse models, explored a novel null null in a model of liver null after null This null null null study was null on null and found that the null inhibitor was able to increase the regeneration null compared with the null These data have the potential to null the way for null clinical studies within the null of null liver null null null null is null a null with potential null and null null after null null these null Nguyen-Lefebvre et al explored null as a potential therapeutic null to increase cell null in the livers after null null and null null null They found that null and null null null in null cell null null et null further null this null by null null as a new potential null to protect against null null Indeed, post-LT biliary null remain the null null of LT and null null is a significant null to the quality of null null In their study, the authors used human null null null to null and null to assess null and cell null They determined null to be an null inhibitor of null and null null by null as well as a null of null null null null was null null to be a null null null null of liver disease in LT null This study null null null to the null underlying null null of liver disease and potential therapeutic null null null In null the quality and null of basic and translational research null have null to null at the ILTS null The null of null research that null mechanistic null into transplantation is critical to null patient outcomes. null null continues to null supply, null is when advances in organ perfusion and null donor LT are essential to null the donor null As nonalcoholic null and HCC null to null as null for LT, new null null null the science null null null with these changes in patient null null null We null null in biomarker research in these null with null null null null techniques, including single-cell sequencing and organ perfusion models to improve organ null will null this null null represents an null opportunity to meet organ null and we null that this research will have a null presence at null ILTS null The Basic and Translational Research Committee fully null null to null and null the null of basic and translational research in LT during the null null of the International Society of Liver null not null with the organization of null and null null but also through null of null has been presented in Congress as this current null In addition, the Committee is null to the null of new null null null between researchers null the year through null and
Type
journal article